New drug TAKHZYRO tracked for Long-Term safety in rare swelling disorder
NCT ID NCT05397431
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 155 people in Japan with hereditary angioedema (HAE) who are taking TAKHZYRO (lanadelumab) injections every two weeks. Researchers will monitor side effects and check if the drug helps control swelling attacks over 12 months. The goal is to see how well TAKHZYRO works in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lanadelumab (TAKHZYRO)
What this could lead to
If successful, this study could confirm that TAKHZYRO is safe and effective for long-term use in controlling HAE attacks.
What could go wrong
This is an observational survey, not a controlled trial, so results may be less definitive. Side effects are still possible, and the study only includes Japanese participants, so findings may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Takeda selected site
Tokyo, Tokyo, Japan